Report: Actelion would consider sale at the right price

Actelion would consider a sale if the price came close to what the company says it's worth, according to Chairman Robert Cawthorn. But the developer has yet to receive an offer, and Cawthorn adds that it's a terrible time to sell, despite pressure from institutional investor Elliott Advisors. "If there ever were an offer to be made for the company that was even close to the value that the board sees in this company...this board would absolutely consider it," added Cawthorn, as quoted by Reuters. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.